Contraindications to Proton Pump Inhibitors
The only absolute contraindication to PPIs is known hypersensitivity or allergic reaction to the specific PPI or its components. Beyond this, there are no formal absolute contraindications, but rather clinical scenarios where PPIs should be avoided or used with extreme caution.
Absolute Contraindications
- Known hypersensitivity/allergic reactions to the specific PPI agent or any component of the formulation 1, 2
- This includes prior anaphylaxis, severe rash, or acute interstitial nephritis attributed to PPI use
Relative Contraindications (Use with Caution or Avoid)
Drug Interactions Requiring Avoidance
- Concurrent use with rilpivirine (HIV medication) - PPIs significantly reduce rilpivirine absorption
- Concurrent use with certain antiretrovirals where acid suppression impairs drug efficacy
- Clopidogrel interaction - though clinical significance remains debated, some PPIs (particularly omeprazole) may reduce clopidogrel's antiplatelet effect through CYP2C19 inhibition 3
Clinical Scenarios Where PPIs Should Not Be Used
Absence of appropriate indication is effectively a contraindication in modern practice 4. The 2022 AGA guidelines explicitly state that without an ongoing indication, PPIs "can only incur harm" through pill burden, costs, and potential adverse effects 4.
Specific "Not Indicated" Scenarios (Avoid Use):
- Empiric treatment of laryngopharyngeal symptoms without proven reflux 4
- Acute undifferentiated abdominal pain 4
- Uninvestigated GERD/dyspepsia as first-line therapy 4
- Any isolated lower GI symptoms 4
- Functional dyspepsia with no sustained response to prior PPI trial 4
Important Clinical Caveats
When to Exercise Extreme Caution (Not Absolute Contraindications)
Severe chronic kidney disease or recurrent acute kidney injury: While not an absolute contraindication, PPIs are associated with both acute interstitial nephritis and progression of chronic kidney disease 1, 2, 3. In patients with advanced CKD, carefully weigh benefits against risks.
Severe osteoporosis with recurrent fractures: Long-term PPI use consistently shows increased fracture risk 1, 2. In patients with severe osteoporosis, consider alternative acid suppression if possible.
Recurrent Clostridioides difficile infection: PPIs increase risk of enteric infections, particularly C. difficile 4, 1, 2. In patients with recurrent C. difficile, discontinue PPIs unless there is a compelling indication (e.g., active GI bleeding, severe erosive esophagitis).
Cirrhotic patients: PPIs may increase complications in cirrhosis, including spontaneous bacterial peritonitis 2, 3. Use only when clearly indicated.
Common Pitfall to Avoid
The most critical error is continuing PPIs without documented indication 4. The 2022 AGA guidelines emphasize that all patients on PPIs should have regular review of ongoing indications, and those without definitive indication should be considered for de-prescribing 4. This represents a paradigm shift: lack of indication is now considered sufficient reason to stop PPIs, rather than requiring evidence of harm.
Algorithm for Determining if PPI Should Be Avoided:
- Is there known hypersensitivity? → If yes, absolute contraindication
- Is there a documented appropriate indication? → If no, do not prescribe/continue
- Are there significant drug interactions? → If yes, avoid or use alternative PPI
- Is the patient at very high risk for PPI-associated complications (advanced CKD, severe osteoporosis, recurrent C. difficile, cirrhosis)? → If yes, use only if benefits clearly outweigh risks for specific indication
The evidence consistently shows PPIs are generally safe medications when appropriately indicated 1, 2, but the key is ensuring an appropriate indication exists and is ongoing 4.